BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Nicox acquires Aciex in stock deal: $65M up front, $55M contingent payments
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Nicox acquires Aciex in stock deal: $65M up front, $55M contingent payments
July 3, 2014
By
Cormac Sheridan
No Comments
Nicox SA is paying $65 million up front and could pay up to $55 million more in a cash-free, stock-based acquisition of Aciex Therapeutics Inc. that gives it a near-term shot at a product approval.
BioWorld